Actively Recruiting
Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients
Led by Cairo University · Updated on 2025-08-12
50
Participants Needed
1
Research Sites
35 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To compare the clinical effectiveness of two different sulbactam-based regimens (ampicillin-sulbactam versus cefoperazone-sulbactam) in the treatment of Acinetobacter baumannii infections in critically ill patients.
CONDITIONS
Official Title
Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 21 years or older
- Patient with signs and symptoms of sepsis
- Positive culture for Carbapenem-resistant Acinetobacter baumannii (CRAB)
You will not qualify if you...
- Receiving empirical sulbactam-based therapy against Gram-negative bacteria
- History of allergic reactions to ampicillin-sulbactam or cefoperazone-sulbactam
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cairo university hospitals kasr alainy
Cairo, Egypt, 11562
Actively Recruiting
Research Team
A
Ayah M Khalil Ibrahem, MSc in clinical pharmacy
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here